Role of transporters in the distribution of platinum-based drugs

被引:76
|
作者
Harrach, Saliha [1 ]
Ciarimboli, Giuliano [1 ,2 ]
机构
[1] Univ Munster, Univ Hosp Munster, Med Clin D, Expt Nephrol, D-48149 Munster, Germany
[2] Univ Munster, Univ Hosp Munster, Interdisciplinary Ctr Clin Res IZKF, D-48149 Munster, Germany
来源
关键词
cisplatin; oxaliplatin; transporters; side effects; uptake; ORGANIC CATION TRANSPORTERS; CISPLATIN-INDUCED NEPHROTOXICITY; ADENOSINE-TRIPHOSPHATASE ATP7B; CELLULAR PHARMACOLOGY; COPPER TRANSPORTERS; OXALIPLATIN; RESISTANCE; CARBOPLATIN; TOXICITY; CTR1;
D O I
10.3389/fphar.2015.00085
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Platinum derivatives used as chemotherapeutic drugs such as cisplatin and oxaliplatin have a potent antitumor activity. However, severe side effects such as nephro-, oto-, and neurotoxicity are associated with their use. Effects and side effects of platinum-based drugs are in part caused by their transporter-mediated uptake in target and non target cells. In this mini review, the transport systems involved in cellular handling of platinum derivatives are illustrated, focusing on transporters for cisplatin. The copper transporter 1 seems to be of particular importance for cisplatin uptake in tumor cells, while the organic cation transporter (OCT) 2, due to its specific organ distribution, may play a major role in the development of undesired cisplatin side effects. In polarized cells, e.g., in renal proximal tubule cells, apically expressed transporters, such as multidrug and toxin extrusion protein 1, mediate secretion of cisplatin and in this way contribute to the control of its toxic effects. Specific inhibition of cisplatin uptake transporters such as the OCTs may be an attractive therapeutic option to reduce its toxicity, without impairing its antitumor efficacy.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Photoactivated platinum-based anticancer drugs
    Imran, Muhammad
    Ayub, Wagma
    Butler, Ian S.
    Zia-ur-Rehman
    COORDINATION CHEMISTRY REVIEWS, 2018, 376 : 405 - 429
  • [2] Nanocapsules of Platinum-Based Anticancer Drugs
    Hamelers, Irene H. L.
    de Kroon, Anton I. P. M.
    PLATINUM AND OTHER HEAVY METAL COMPOUNDS IN CANCER CHEMOTHERAPY: MOLECULAR MECHANISMS AND CLINICAL APPLICATIONS, 2009, : 27 - +
  • [3] Click chelators for platinum-based anticancer drugs
    Maisonial, Aurelie
    Serafin, Patrycja
    Traikia, Mounir
    Debiton, Eric
    Thery, Vincent
    Aitken, David J.
    Lemoine, Pascale
    Viossat, Bernard
    Gautier, Arnaud
    EUROPEAN JOURNAL OF INORGANIC CHEMISTRY, 2008, (02) : 298 - 305
  • [4] Platinum-Based Nanoformulations for Glioblastoma Treatment: The Resurgence of Platinum Drugs?
    Alfonso-Triguero, Paula
    Lorenzo, Julia
    Candiota, Ana Paula
    Arus, Carles
    Ruiz-Molina, Daniel
    Novio, Fernando
    NANOMATERIALS, 2023, 13 (10)
  • [5] The influence of platinum-based drugs on the amount of metallothionein
    Prusa, R.
    Blastik, O.
    Kukacka, J.
    Zehnalek, J.
    Adam, V.
    Petrlova, J.
    Kizek, R.
    TOXICOLOGY LETTERS, 2005, 158 : S66 - S67
  • [6] Current status of platinum-based antitumor drugs
    Wong, E
    Giandomenico, CM
    CHEMICAL REVIEWS, 1999, 99 (09) : 2451 - 2466
  • [7] Chemical Imaging of Platinum-Based Drugs and their Metabolites
    Xin Liu
    Amanda B. Hummon
    Scientific Reports, 6
  • [8] Chemical Imaging of Platinum-Based Drugs and their Metabolites
    Liu, Xin
    Hummon, Amanda B.
    SCIENTIFIC REPORTS, 2016, 6
  • [9] Platinum-based drugs: past, present and future
    Dilruba, Shahana
    Kalayda, Ganna V.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 77 (06) : 1103 - 1124
  • [10] Platinum-based drugs: past, present and future
    Shahana Dilruba
    Ganna V. Kalayda
    Cancer Chemotherapy and Pharmacology, 2016, 77 : 1103 - 1124